4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Nkarta, Inc. (NKTX) operates in the Biotechnology industry and is headquartered in South San Francisco, United States with about 108 employees. Its market capitalization is roughly $231 million. In the fiscal year ended 2025-12-31, NKTX reported $0M in revenue and ($104M) in net income.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($122M) | ($128M) | ($132M) | ($119M) |
| Net Income | ($104M) | ($109M) | ($118M) | ($114M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($31M) | ($31M) | ($27M) | ($27M) | ($37M) |
| Net Income | ($28M) | ($27M) | ($22M) | ($23M) | ($32M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $404M | $501M | $379M | $473M | — |
| Total Liabilities | $92M | $93M | $106M | $101M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NKTX viewer.
About TickerBase · Data methodology & sources